Cancer Surveillance and Pharmacoepidemiology

The group Cancer Surveillance and Pharmacoepidemiology uses high-quality Nordic registry data as basis for their research

Within the Cancer Surveillance Program, registry data is processed on cancer incidence, prevalence, mortality and survival statistics.

Ongoing projects include Nordic studies aiming for identification of “reasons for differences in cancer survival”, and collaborative research projects include e.g. CONCORD-3, and SurvMark-2.

The team also make descriptive data on cancer statistics public available through e.g. NORDCAN, which is an interactive and user-friendly web-based tool (

Within the Pharmacoepidemiological Research Program, Nordic registry data is processed on safety, risks and benefits of commonly used drugs. Drug candidates include prescription drugs used by men, women or children; and in early pregnancy.

Ongoing projects include safety studies of drug use “up to” or “in” pregnancy and an array of studies focusing on possibilities of repurposing of drugs with potential anti-cancer effects, whether in cancer prevention or as beneficial effects on cancer prognosis.

We are also interested in potential carcinogenic effects of drug use, and we are currently seeking to improve methods of exploring prognostic effects of drug use within a general screening program of drug use among cancer patients.

Cancer Surveillance and Pharmacoepidemiology

PhD, Msc in Public Health, Lina Mørch, heads Cancer Surveillance and Pharmacoepidemiology. Her work is within cancer-, reproductive- and pharmaco-epidemiology, and she has taken a special interest in the influence of postmenopausal hormone therapy and hormonal contraceptives on cancer risk. This also include other health effects in women and their children of exposure to prescription drugs. 

Group members

Senior Researcher Søren Friis 
Senior Statistician Gerda Engholm 
Data Manager Charlotte Wessel Skovlund  
Postdoc Charlotte Skriver 

Five selected publications:

Arnold, M., Rutherford, M. J., Bardot, A., Ferlay, J., Andersson, T. M., Myklebust, T. A., Tervonen, H., Thursfield, V., Ransom, D., Shack, L., Woods, R. R., Turner, D., Leonfellner, S., Ryan, S., Saint-Jacques, N., De, P., McClure, C., Ramanakumar, A. V., Stuart-Panko, H., Engholm, G., Walsh, P. M., Jackson, C., Vernon, S., Morgan, E., Gavin, A., Morrison, D. S., Huws, D. W., Porter, G., Butler, J., Bryant, H., Currow, D. C., Hiom, S., Parkin, D. M., Sasieni, P., Lambert, P. C., Moller, B., Soerjomataram, I., Bray, F.
Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study.
Lancet Oncol. 2019: 20(11), 1493-1505

Skriver, C., Dehlendorff, C., Borre, M., Brasso, K., Larsen, S. B., Dalton, S. O., Norgaard, M., Pottegard, A., Hallas, J., Sorensen, H. T., Friis, S.
Use of Low-Dose Aspirin and Mortality After Prostate Cancer Diagnosis: A Nationwide Cohort Study.
Ann.Intern.Med. 2019: 170(7), 443-452

Lokkegaard, E. C. L. Morch, L. S.
Tibolone and risk of gynecological hormone sensitive cancer.
Int.J.Cancer 2018: 142(12), 2435-2440

Morch, L. S., Skovlund, C. W., Hannaford, P. C., Iversen, L., Fielding, S., Lidegaard, O.
Contemporary Hormonal Contraception and the Risk of Breast Cancer.
N.Engl.J.Med. 2017: 377(23), 2228-2239

Friis, S., Riis, A. H., Erichsen, R., Baron, J. A., Sorensen, H. T.
Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drug Use and Colorectal Cancer Risk: A Population-Based, Case-Control Study.
Ann.Intern.Med. 2015: 163(5), 347-355